Document is current

Article History

Received: 5 August 2024

Accepted: 13 January 2025

First Online: 24 February 2025

Declarations

:

: All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The survey protocol was submitted to the Western IRB-Copernicus Group (WCG) and received an IRB exemption on June 22, 2022 under 45 CFR § 46.104(d)(2). Informed consent was obtained from all individual participants involved in the study.

: Not applicable.

: L. C-S has received consulting fees and/or honoraria from Abcuro, Allogene, AlloNK, Amgen, Argenx, BoehringerIngelheim, BMS, Chugai, the Dysimmune Disease Foundation, Gallapagos, Immunovant, Janssen, Mallinckrodt, Nkarta, Nuvig, Octapharma, Priovant Therapeutics, Roivant Sciences, Steritas, and EMD Serono, and research support from Abcuro, Corbus Pharmaceuticals, Kezar Life Sciences, and Pfizer Inc.J.J. P has received research support from Argenx Corbus Pharmaceuticals, Kezar Life Sciences, and Pfizer Inc.; consulting fees and/or honoraria from Argenx, Alexion, EMD Serono, Guidepoint Consulting, Pfizer Inc., Priovant Therapeutics, and Roivant Sciences, and is supported by grant number K23AR073927 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). P.N M Jr. and A.S G are employees of Priovant Therapeutics. J.J. Paik has received research support from Argenx Corbus Pharmaceuticals, Kezar Life Sciences, and Pfizer Inc.; consulting fees and/or honoraria from Argenx, Alexion, EMD Serono, Guidepoint Consulting, Pfizer Inc., Priovant Therapeutics, and Roivant Sciences, and is supported by grant number K23AR073927 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). P.N Mudd Jr. and A.S Goriounova are employees of Priovant Therapeutics.